Europe Personalized Medicine Biomarkers Market by Product Type, End-Use, and Country-wise Insights: Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031

Description

Persistence Market Research has recently released a comprehensive report on the European market for Personalized Medicine Biomarkers. This report provides an in-depth analysis of key market dynamics, including drivers, trends, opportunities, and challenges, offering detailed insights into the market structure. The publication also includes exclusive data and forecasts, mapping the anticipated growth trajectory of the European Personalized Medicine Biomarkers Market from 2024 to 2031.

Key Insights:

Europe Personalized Medicine Biomarkers Market Size (2024E): US$5.2 Bn
Projected Market Value (2031F): US$14.1 Bn
Regional Market Growth Rate (CAGR 2024 to 2031): 15.3%

Europe Personalized Medicine Biomarkers Market - Report Scope:

Personalized medicine biomarkers play a crucial role in tailoring healthcare treatments to individual patients by identifying specific biomarkers linked to disease processes or therapeutic responses. In the European market, personalized medicine biomarkers are increasingly being used in oncology, cardiology, neurology, and other therapeutic areas to enable more precise, effective, and customized treatments. The market's growth is driven by advances in genomics, biotechnology, and diagnostics, coupled with the increasing demand for personalized healthcare solutions.

Market Growth Drivers:

The European personalized medicine biomarkers market is propelled by several factors, including advancements in genomics and biotechnology, growing adoption of precision medicine, and increasing demand for tailored treatments. The rising prevalence of chronic diseases, particularly cancer, cardiovascular disorders, and neurodegenerative conditions, has led to greater investment in personalized medicine initiatives. Furthermore, innovations in diagnostic technologies, such as next-generation sequencing (NGS), and the use of artificial intelligence (AI) in biomarker discovery are accelerating market growth. The growing emphasis on preventive healthcare and personalized therapies in the region further contributes to market expansion.

Market Restraints:

Despite promising growth, the European market for personalized medicine biomarkers faces challenges, such as the high cost of biomarker-based diagnostics and treatments, regulatory hurdles, and the complexity of integrating personalized medicine into healthcare systems. The lack of standardization in biomarker testing, data privacy concerns, and ethical considerations around genetic data may also slow the widespread adoption of personalized medicine. Additionally, the availability of affordable and accessible biomarkers is still a challenge for many healthcare providers, particularly in emerging markets within Europe.

Market Opportunities:

The personalized medicine biomarkers market in Europe presents significant growth opportunities driven by innovations in genomic research and technology. The increasing use of AI and machine learning in biomarker discovery, combined with advances in molecular diagnostics, offers immense potential for accelerating the development of personalized treatments. Additionally, the expansion of targeted therapies in oncology and the growing popularity of companion diagnostics provide new opportunities for personalized medicine biomarker applications. Furthermore, partnerships between pharmaceutical companies, biotechnology firms, and research institutions in Europe are creating avenues for the development of novel biomarkers, contributing to the overall market growth.

Key Questions Answered in the Report:

What are the primary drivers of growth in the European personalized medicine biomarkers market?
How are advancements in genomic research and biotechnology transforming the market?
Who are the key players in the European personalized medicine biomarkers market, and what strategies are they using to maintain their competitive advantage?
What are the emerging trends and future prospects in the European personalized medicine biomarkers market?
How are market players addressing regulatory challenges and the integration of biomarkers in healthcare systems?

Competitive Intelligence and Business Strategy:

Leading companies in the European personalized medicine biomarkers market, including Laboratory Corporation of America Holding,Quest Diagnostics Incorporated, Genome Medical, Inc., and Coriell Life Sciences., are focusing on product innovation and strategic partnerships to strengthen their market positions. These companies are investing heavily in research and development to introduce advanced biomarker discovery platforms and personalized medicine diagnostic tools. Additionally, collaborations with academic institutions, healthcare providers, and biotechnology firms play a key role in expanding their reach and advancing the development of new biomarker-based therapies. Moreover, the growing trend of integrating AI and machine learning technologies is enabling these companies to optimize biomarker identification and enhance treatment personalization.

Key Companies Profiled:

Laboratory Corporation of America Holding
Quest Diagnostics Incorporated
Agilent Technologies, Inc.
Genome Medical, Inc.
Coriell Life Sciences.
Roche Diagnostics
NeoGenomics Laboratories
FOUNDATION MEDICINE, INC.
Illumina, Inc.
Guardant Health
PerkinElmer
Bio-Rad Laboratories
GE Healthcare
Qiagen
Thermo Fisher Scientific Inc.

Europe Personalized Medicine Biomarkers Market Segmentation

By Application

Diagnosis
Monitoring
Early Detection/Screening
Treatment Selection
Others

By Indication

Oncology Diseases
Autoimmune Diseases
Cardiology
Diabetes
Neurology
Others

By Country

Germany
France
U.K.
Italy
Spain
Russia
Rest of Europe

Product Code: PMRREP34951

1. Executive Summary

1.1. Europe Personalized Medicine Biomarkers Market Snapshot, 2024 - 2031
1.2. Market Opportunity Assessment, 2024 - 2031, US$ Bn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations

2. Market Overview

2.1. Market Scope and Definition
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Opportunity
- 2.2.4. Key Trends
2.3. Macro-Economic Factors
- 2.3.1. Europe Sectorial Outlook
- 2.3.2. Europe GDP Growth Outlook
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

3.1. Product Adoption Analysis
3.2. Recent Product Approvals and Launches Insights
3.3. Regulatory Landscape
3.4. Value Chain Analysis
3.5. PESTLE Analysis
3.6. Porter's Five Force Analysis

4. Europe Personalized Medicine Biomarkers Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

4.1. Key Highlights
- 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
- 4.1.2. Absolute $ Opportunity
4.2. Market Size (US$ Bn) Analysis and Forecast
- 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019 - 2023
- 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2024 - 2031
4.3. Europe Personalized Medicine Biomarkers Market Outlook: Application
- 4.3.1. Introduction / Key Findings
- 4.3.2. Historical Market Size (US$ Bn) Analysis, By Application, 2019 - 2023
- 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024 - 2031
  - 4.3.3.1. Diagnosis
  - 4.3.3.2. Monitoring
  - 4.3.3.3. Early Detection/Screening
  - 4.3.3.4. Treatment Selection
  - 4.3.3.5. Others
- 4.3.4. Market Attractiveness Analysis: Application
4.4. Europe Personalized Medicine Biomarkers Market Outlook: Indication
- 4.4.1. Introduction / Key Findings
- 4.4.2. Historical Market Size (US$ Bn) Analysis, By Indication, 2019 - 2023
- 4.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024 - 2031
  - 4.4.3.1. Oncology Diseases
  - 4.4.3.2. Autoimmune Diseases
  - 4.4.3.3. Cardiology
  - 4.4.3.4. Diabetes
  - 4.4.3.5. Neurology
  - 4.4.3.6. Others
- 4.4.4. Market Attractiveness Analysis: Indication

5. Europe Personalized Medicine Biomarkers Market Outlook: Country

5.1. Key Highlights
5.2. Historical Market Size (US$ Bn) Analysis, By Country, 2019 - 2023
5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024 - 2031
- 5.3.1. Germany
- 5.3.2. France
- 5.3.3. U.K.
- 5.3.4. Italy
- 5.3.5. Spain
- 5.3.6. Russia
- 5.3.7. Rest of Europe
5.4. Market Attractiveness Analysis: Country

6. Germany Europe Personalized Medicine Biomarkers Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

6.1. Key Highlights
6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
- 6.2.1. By Application
- 6.2.2. By Indication
6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024 - 2031
- 6.3.1. Diagnosis
- 6.3.2. Monitoring
- 6.3.3. Early Detection/Screening
- 6.3.4. Treatment Selection
- 6.3.5. Others
6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024 - 2031
- 6.4.1. Oncology Diseases
- 6.4.2. Autoimmune Diseases
- 6.4.3. Cardiology
- 6.4.4. Diabetes
- 6.4.5. Neurology
- 6.4.6. Others
6.5. Market Attractiveness Analysis

7. France Europe Personalized Medicine Biomarkers Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

7.1. Key Highlights
7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
- 7.2.1. By Application
- 7.2.2. By Indication
7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024 - 2031
- 7.3.1. Diagnosis
- 7.3.2. Monitoring
- 7.3.3. Early Detection/Screening
- 7.3.4. Treatment Selection
- 7.3.5. Others
7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024 - 2031
- 7.4.1. Oncology Diseases
- 7.4.2. Autoimmune Diseases
- 7.4.3. Cardiology
- 7.4.4. Diabetes
- 7.4.5. Neurology
- 7.4.6. Others
7.5. Market Attractiveness Analysis

8. UK Europe Personalized Medicine Biomarkers Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

8.1. Key Highlights
8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
- 8.2.1. By Application
- 8.2.2. By Indication
8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024 - 2031
- 8.3.1. Diagnosis
- 8.3.2. Monitoring
- 8.3.3. Early Detection/Screening
- 8.3.4. Treatment Selection
- 8.3.5. Others
8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024 - 2031
- 8.4.1. Oncology Diseases
- 8.4.2. Autoimmune Diseases
- 8.4.3. Cardiology
- 8.4.4. Diabetes
- 8.4.5. Neurology
- 8.4.6. Others
8.5. Market Attractiveness Analysis

9. Italy Europe Personalized Medicine Biomarkers Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

9.1. Key Highlights
9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
- 9.2.1. By Application
- 9.2.2. By Indication
9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024 - 2031
- 9.3.1. Diagnosis
- 9.3.2. Monitoring
- 9.3.3. Early Detection/Screening
- 9.3.4. Treatment Selection
- 9.3.5. Others
9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024 - 2031
- 9.4.1. Oncology Diseases
- 9.4.2. Autoimmune Diseases
- 9.4.3. Cardiology
- 9.4.4. Diabetes
- 9.4.5. Neurology
- 9.4.6. Others
9.5. Market Attractiveness Analysis

10. Spain Europe Personalized Medicine Biomarkers Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

10.1. Key Highlights
10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
- 10.2.1. By Application
- 10.2.2. By Indication
10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024 - 2031
- 10.3.1. Diagnosis
- 10.3.2. Monitoring
- 10.3.3. Early Detection/Screening
- 10.3.4. Treatment Selection
- 10.3.5. Others
10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024 - 2031
- 10.4.1. Oncology Diseases
- 10.4.2. Autoimmune Diseases
- 10.4.3. Cardiology
- 10.4.4. Diabetes
- 10.4.5. Neurology
- 10.4.6. Others
10.5. Market Attractiveness Analysis

11. Russia Europe Personalized Medicine Biomarkers Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

11.1. Key Highlights
11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
- 11.2.1. By Application
- 11.2.2. By Indication
11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024 - 2031
- 11.3.1. Diagnosis
- 11.3.2. Monitoring
- 11.3.3. Early Detection/Screening
- 11.3.4. Treatment Selection
- 11.3.5. Others
11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024 - 2031
- 11.4.1. Oncology Diseases
- 11.4.2. Autoimmune Diseases
- 11.4.3. Cardiology
- 11.4.4. Diabetes
- 11.4.5. Neurology
- 11.4.6. Others
11.5. Market Attractiveness Analysis

12. Competition Landscape

12.1. Market Share Analysis, 2023
12.2. Market Structure
- 12.2.1. Competition Intensity Mapping By Market
- 12.2.2. Competition Dashboard
12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
- 12.3.1. Illumina, Inc.
  - 12.3.1.1. Overview
  - 12.3.1.2. Segments and Product
  - 12.3.1.3. Key Financials
  - 12.3.1.4. Market Developments
  - 12.3.1.5. Market Strategy
- 12.3.2. Laboratory Corporation of America Holding
- 12.3.3. Quest Diagnostics Incorporated
- 12.3.4. Agilent Technologies, Inc.
- 12.3.5. Genome Medical, Inc.
- 12.3.6. Coriell Life Sciences.
- 12.3.7. Roche Diagnostics
- 12.3.8. NeoGenomics Laboratories
- 12.3.9. FOUNDATION MEDICINE, INC.
- 12.3.10. Guardant Health
- 12.3.11. PerkinElmer
- 12.3.12. Bio-Rad Laboratories
- 12.3.13. GE Healthcare
- 12.3.14. Qiagen
- 12.3.15. Thermo Fisher Scientific Inc.

13. Appendix

13.1. Research Methodology
13.2. Research Assumptions
13.3. Acronyms and Abbreviations